Mymetics Receives Support for Virosome-based Covid-19 vaccine development from European Vaccine Infrastructure project (Transvac2)
Epalinges, Switzerland, June 11, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer
and leader in the research and development of virosome-based vaccines against life
threatening and life disabling diseases, announced today that its subsidiary, Mymetics SA,
has received the confirmation to receive access to the European vaccine infrastructure
TRANSVAC2 services for the evaluation and development of virosome-based vaccines
against Covid-19, the disease caused by SARS-CoV-2.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Press Release pdf | Download |